文献速递核素与放射性配体治疗肿瘤 PET/CT

数字固态SPECT/CT对177Lu放射性示踪剂绝对浓度的定量:体内与体外验证

Digital Solid-State SPECT/CT Quantitation of Absolute 177Lu Radiotracer Concentration: In Vivo and In Vitro Validation.
PubMed 文献 · J Nucl Med · 2020-02-28

该研究在数字固态碲锌镉SPECT/CT系统上,通过体模评估采集参数,并回顾性分析7例接受177Lu前列腺特异性膜抗原放射配体治疗的28次全身SPECT/CT扫描,比较体内膀胱放射性摄取与体外尿样浓度的线性关系。结果显示,仅使用113 keV能量峰时定量误差更低,体内外关系符合恒等关系,平均残差差异为19.5%,准确度约在20%以内。

要点

  • 体模结果显示,仅用113 keV峰采集的定量误差低于纳入208 keV峰。
  • 24对体内外数据线性回归R²≥0.82,P<0.0001,符合恒等关系。
  • 所有用户SUV平均值斜率为0.96±0.13,截距为-0.07±0.46 g/mL,平均残差差异19.5%。

核心结论

  • 这种无创体内定量方法可能改善诊断、患者管理和治疗反应评估,并为177Lu剂量测定提供关键数据。

研究设计与样本

  • 回顾性分析7例接受177Lu前列腺特异性膜抗原放射配体治疗患者的28次全身SPECT/CT扫描数据,使用数字固态碲锌镉SPECT/CT系统。
  • 首先在模拟临床计数率的国际电工委员会体模上评估图像采集参数,体模含肺插入物和6个热球,目标本底比为12:1的177Lu溶液。
  • 由三名用户使用定量软件分析SPECT/CT图像中的体内膀胱放射性摄取,并通过每次扫描后立即采集的尿样计算体外放射性药物浓度,换算为SUVs。

主要发现

  • 体模结果显示,在仅配备低能准直器的该相机配置下,使用113 keV的177Lu能量峰采集的定量误差低于纳入208 keV峰。
  • 临床研究中,24对体内外数据符合进一步分析条件,4对被Cook距离计算判定为离群值而剔除。
  • 所有线性回归R²≥0.82,P<0.0001,体内外关系符合恒等关系(95%置信区间),所有用户SUV平均值斜率为0.96±0.13,截距为-0.07±0.46 g/mL,平均残差差异为19.5%。
  • 在较低能量177Lu能量峰采集时,固态SPECT/CT成像对体内膀胱放射性示踪剂浓度的准确度约在20%以内。

关键数值与推荐

  • 线性回归理想斜率为1、截距为0,结果以95%置信区间评估。
  • 体模热球目标本底比为12:1的177Lu溶液。
  • 临床分析中24对体内外数据纳入,4对因离群值剔除。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究为回顾性分析。
  • 仅7例患者共28次扫描,样本量有限。
  • 4对数据因离群值被剔除。
  • 原文结论使用「can potentially improve」的限定表述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The accuracy of 177Lu radiotracer concentration measurements using quantitative clinical software was determined by comparing in vivo results for a digital solid-state cadmium-zinc-telluride SPECT/CT system with in vitro sampling. Methods: First, image acquisition parameters were assessed for an International Electrotechnical Commission body phantom emulating clinical count rates loaded with a lung insert and 6 hot spheres with a 12:1 target-to-background ratio of 177Lu solution. Then, the data of 28 whole-body SPECT/CT scans of 7 patients who underwent 177Lu prostate-specific membrane antigen radioligand therapy were retrospectively analyzed. Three users analyzed SPECT/CT images for in vivo urinary bladder radiotracer uptake using quantitative software. In vitro radiopharmaceutical concentrations were calculated using urine sampling obtained immediately after each scan, scaled to SUVs. Any in vivo or in vitro identity relations were determined by linear regression (ideally, slope = 1 and intercept = 0), within a 95% confidence interval. Results: Phantom results demonstrated lower quantitative error for acquisitions using the 113-keV 177Lu energy peak rather than including the 208-keV peak, given that only low-energy collimation was available in this camera configuration. In the clinical study, 24 in vivo-in vitro pairs were eligible for further analysis, with 4 having been rejected as outliers (via Cook distance calculations). All linear regressions (R2 ≥ 0.82, P < 0.0001) provided identity in vivo-in vitro relations (95% confidence interval), with SUV averages from all users giving a slope of 0.96 ± 0.13, an intercept of -0.07 ± 0.46 g/mL, and an average residual difference of 19.5%. In acquisitions with the lower-energy 177Lu energy peak, solid-state SPECT/CT imaging provided an accuracy to within approximately 20% of in vivo urinary bladder radiotracer concentrations. Conclusion: This noninvasive in vivo quantitation method can potentially improve diagnosis, patient management, and treatment response assessment and provide data essential to 177Lu dosimetry.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kennedy JA, Lugassi R, Gill R, et al. Digital Solid-State SPECT/CT Quantitation of Absolute 177Lu Radiotracer Concentration: In Vivo and In Vitro Validation. J Nucl Med. 2020. PMID: 32111686. doi:10.2967/jnumed.119.239277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。